TABLE 1.
Cohort Overview
| Before Propensity Score Matching | After Propensity Score Matching | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Characteristics | MACE | No MACE | SMD | MACE | No MACE | SMD | ||||
| N | 900 | 38.847 | 809 | 809 | ||||||
| Age, years | ||||||||||
| ≤49 | <6 | 0% | 1.482 | 4% | −0.26 | <6 | 0% | 9 | 1% | −0.11 |
| 50–74 | 398 | 44% | 22.928 | 59% | −0.30 | 373 | 46% | 355 | 44% | −0.04 |
| ≥75 | 500 | 56% | 14.437 | 37% | 0.38 | 434 | 54% | 445 | 55% | 0.03 |
| Sex | ||||||||||
| Female | 329 | 37% | 17.932 | 46% | −0.20 | 294 | 36% | 292 | 36% | 0.01 |
| Male | 571 | 63% | 20.915 | 54% | 0.20 | 515 | 64% | 517 | 64% | −0.01 |
| BMI | ||||||||||
| ≤18.5 | 21 | 2% | 999 | 3% | −0.02 | 17 | 2% | 17 | 2% | 0.00 |
| >18.5–≤25.0 | 318 | 35% | 14.975 | 39% | −0.07 | 289 | 36% | 279 | 34% | 0.03 |
| >25.0–≤30.0 | 291 | 32% | 12.874 | 33% | −0.02 | 270 | 33% | 282 | 35% | −0.03 |
| >30.0–≤35.0 | 104 | 12% | 4.445 | 11% | 0.00 | 97 | 12% | 93 | 11% | 0.02 |
| >35.0 | 37 | 4% | 1.540 | 4% | 0.01 | 31 | 4% | 40 | 5% | −0.05 |
| Missing | 129 | 14% | 4.014 | 10% | N/A | 105 | 13% | 98 | 12% | N/A |
| Charlson comorbidity index | ||||||||||
| 0 | 298 | 33% | 24.732 | 64% | −0.64 | 265 | 33% | 241 | 30% | 0.06 |
| 1 | 253 | 28% | 6.670 | 17% | 0.26 | 238 | 29% | 229 | 28% | 0.02 |
| 2 | 157 | 17% | 4.024 | 10% | 0.21 | 144 | 18% | 148 | 18% | −0.01 |
| 3 | 188 | 21% | 3.376 | 9% | 0.35 | 158 | 20% | 189 | 23% | −0.09 |
| Missing | <6 | 0% | 45 | 0% | N/A | <6 | 0% | <6 | 0% | N/A |
| WHO Performance status | ||||||||||
| 0 | 152 | 17% | 11.050 | 28% | −0.28 | 146 | 18% | 114 | 14% | 0.01 |
| 1 | 122 | 14% | 3.778 | 10% | 0.12 | 111 | 14% | 134 | 17% | −0.08 |
| 2 | 67 | 7% | 1.000 | 3% | 0.22 | 62 | 8% | 38 | 5% | 0.12 |
| 3 | 9 | 1% | 218 | 1% | 0.05 | 7 | 1% | 11 | 1% | 0.05 |
| 4 | <6 | 0% | 37 | 0% | N/A | <6 | 0% | <6 | 0% | N/A |
| Missing | 550 | 61% | 22.764 | 59% | N/A | 483 | 60% | 511 | 63% | N/A |
| ASA | ||||||||||
| 1 | 46 | 5% | 8.900 | 23% | −0.53 | 42 | 5% | 32 | 4% | 0.06 |
| 2 | 388 | 43% | 21.810 | 56% | −0.26 | 356 | 44% | 353 | 44% | 0.01 |
| 3 | 413 | 46% | 7.343 | 19% | 0.60 | 366 | 45% | 403 | 50% | −0.09 |
| 4 | 31 | 3% | 311 | 1% | 0.18 | 25 | 3% | 11 | 1% | 0.12 |
| 5 | N/A | % | 9 | 0% | N/A | N/A | % | N/A | % | N/A |
| Missing | 22 | 2% | 474 | 1% | N/A | 20 | 2% | 10 | 1% | N/A |
| Pathologic UICC stage | ||||||||||
| 1 | 171 | 19% | 8.093 | 21% | −0.05 | 158 | 20% | 138 | 17% | 0.06 |
| 2 | 320 | 36% | 13.772 | 35% | 0.00 | 279 | 34% | 304 | 38% | −0.06 |
| 3 | 286 | 32% | 11.585 | 30% | 0.04 | 259 | 32% | 258 | 32% | 0.00 |
| 4 | 123 | 14% | 5.397 | 14% | 0.00 | 113 | 14% | 109 | 13% | 0.01 |
| Tumor location | ||||||||||
| Rectum | 273 | 30% | 12.556 | 32% | −0.04 | 251 | 31% | 244 | 30% | 0.02 |
| Sigmoid colon | 249 | 28% | 10.888 | 28% | 0.01 | 226 | 28% | 227 | 28% | 0.00 |
| Descending colon | 50 | 6% | 2.329 | 6% | 0.02 | 42 | 5% | 46 | 6% | −0.02 |
| Transverse colon | 51 | 6% | 2.110 | 5% | 0.01 | 48 | 6% | 51 | 6% | −0.02 |
| Ascending colon | 171 | 19% | 6.086 | 16% | 0.09 | 146 | 18% | 133 | 16% | 0.04 |
| Cecum | 107 | 12% | 4.988 | 13% | −0.03 | 96 | 12% | 106 | 13% | −0.04 |
Baseline characteristics of the population undergoing surgery for colorectal cancer. Data are expressed as No. (%).
ASA indicates American Society of Anesthesiologist’s physical status classification system; UICC: Union for International Cancer Control.